









Markets
/
Stocks
/
nasdaq-dare
/

Dare Bioscience Inc

DARE

1.820USD

-0.010-0.55%

Close 11/10, 16:00（ET）Quotes delayed by 15 min

16.44MMarket Cap

LossP/E TTM



Dare Bioscience Inc

1.820

-0.010-0.55%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Dare Bioscience Inc

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company shows weak stock market performance, in line with its weak fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dare Bioscience Inc's Score

Industry at a Glance

Industry Ranking

107 / 159

Overall Ranking

291 / 4611

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

10.750

Target Price

+487.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Dare Bioscience Inc Highlights

StrengthsRisks

Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.78K.

Overvalued

The company’s latest PE is -0.18, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.00M shares, decreasing 32.47% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 71.80K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.66.

Financial Health

Currency: USD Updated: 2025-11-10

The company's current financial score is 5.74, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.74

Change



Financials

5.53

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.12

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.35

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.13

Key Metrics

Free cash flow

No Data

Dare Bioscience Inc's Company Valuation

Currency: USD Updated: 2025-11-10

The company’s current valuation score is 7.74, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -0.18, which is -439.48% below the recent high of 0.61 and -10583.25% above the recent low of -19.13.

Score

Industry at a Glance

Previous score

7.74

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 107/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-10

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Dare Bioscience Inc is 11.50, with a high of 12.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

10.750

Target Price

+487.43%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Dare Bioscience Inc

DARE

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-10

The company’s current price momentum score is 5.49, which is lower than the Pharmaceuticals industry's average of 7.09. Sideways: Currently, the stock price is trading between the resistance level at 2.15 and the support level at 1.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.14

Change

0.35

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.042

Sell

RSI(14)

33.979

Neutral

STOCH(KDJ)(9,3,3)

17.063

Neutral

ATR(14)

0.098

High Vlolatility

CCI(14)

-106.322

Sell

Williams %R

84.181

Oversold

TRIX(12,20)

-0.547

Sell

StochRSI(14)

84.216

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.822

Sell

MA10

1.897

Sell

MA20

1.985

Sell

MA50

2.069

Sell

MA100

2.218

Sell

MA200

2.607

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-10

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 7.45%, representing a quarter-over-quarter decrease of 34.00%. The largest institutional shareholder is The Vanguard, holding a total of 394.90K shares, representing 2.93% of shares outstanding, with 11.69% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

328.33K

AMH Equity, Ltd.

193.60K

+17.83%

Susquehanna International Group, LLP

106.89K

+83.77%

Geode Capital Management, L.L.C.

95.45K

-0.47%

Johnson (Sabrina Martucci)

80.17K

+0.00%

Renaissance Technologies LLC

Star Investors

71.80K

+1.70%

Walters-Hoffert (Lisa)

36.96K

State Street Investment Management (US)

23.52K

Steele Robin Joan

20.52K

+0.00%

Risk Assessment

Currency: USD Updated: 2025-11-10

The company’s current risk assessment score is 3.36, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.77. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.